» Articles » PMID: 39500829

Barriers in Healthcare to the Use of Optical Coherence Tomography Angiography in Multiple Sclerosis

Overview
Journal Neurol Ther
Publisher Springer
Specialty Neurology
Date 2024 Nov 5
PMID 39500829
Authors
Affiliations
Soon will be listed here.
Abstract

Optical coherence tomography angiography (OCT-A) is a state-of-the-art imaging technique for the retinal vasculature to accurately segment the capillary network and assign it to retinal layers. OCT-A is a promising technique to better understand neurological diseases with visual system manifestations, such as multiple sclerosis (MS), and to identify and characterize vascular biomarkers. Initial studies suggested vascular changes in MS and its differential diagnoses such as myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD). Here we review clinical and technical aspects of OCT-A imaging and discuss the potential for the MS field as well as barriers that need to be overcome before OCT-A can be established in clinical application.

References
1.
Goldenberg D, Shahar J, Loewenstein A, Goldstein M . Diameters of retinal blood vessels in a healthy cohort as measured by spectral domain optical coherence tomography. Retina. 2013; 33(9):1888-94. DOI: 10.1097/IAE.0b013e31829477f2. View

2.
Kappos L, Wolinsky J, Giovannoni G, Arnold D, Wang Q, Bernasconi C . Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020; 77(9):1132-1140. PMC: 7281382. DOI: 10.1001/jamaneurol.2020.1568. View

3.
Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R . Diagnosis and classification of optic neuritis. Lancet Neurol. 2022; 21(12):1120-1134. DOI: 10.1016/S1474-4422(22)00200-9. View

4.
Oliverio G, Meduri A, De Salvo G, Trombetta L, Aragona P . OCT Angiography Features in Diabetes Mellitus Type 1 and 2. Diagnostics (Basel). 2022; 12(12). PMC: 9777069. DOI: 10.3390/diagnostics12122942. View

5.
Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer S . Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT). Front Immunol. 2024; 15:1380025. PMC: 11253107. DOI: 10.3389/fimmu.2024.1380025. View